You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIMC-A12
Accession NumberDB05759
TypeBiotech
GroupsInvestigational
DescriptionIMC-A12 is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumour types. It is developed for the treatment of advanced solid tumors.
Protein structureNo structure small
Related Articles
Protein chemical formulaNot Available
Protein average weightNot Available
SequencesNot Available
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIINot Available
CAS numberNot Available
Pharmacology
IndicationInvestigated for use/treatment in colorectal cancer and prostate cancer.
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionIMC-A12 is a fully human monoclonal antibody that specifically targets the type 1 human insulin-like growth factor receptor (IGF-IR). Tumors have receptors for the insulin-like growth factor-1 (IGF-I), and it is thought that the presence of these receptors cause tumors to grow. IMC-A12 attaches to the receptors and may inhibit the growth of cancer cells.
TargetKindPharmacological actionActionsOrganismUniProt ID
Insulin-like growth factor 1 receptorProteinunknownNot AvailableHumanP08069 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life148 h (3 mg/kg dose level) 209 h (6mg/kg dose level)
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with IMC-A12.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with IMC-A12.Investigational
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with IMC-A12.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with IMC-A12.Investigational
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with IMC-A12.Approved
RindopepimutThe therapeutic efficacy of CDX-110 can be decreased when used in combination with IMC-A12.Investigational
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with IMC-A12.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with IMC-A12.Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL: IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5549s-5555s. [PubMed:17875788 ]
  2. Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, Patel D, Kang X, Ludwig DL, Hicklin DJ, Bohlen P, Witte L, Zhu Z: A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem. 2005 May 20;280(20):19665-72. Epub 2005 Mar 9. [PubMed:15757893 ]
External LinksNot Available
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentNeoplasms, Malignant1
1WithdrawnTreatmentGliomas / Neoplasms, Brain Stem / Pinealoma1
2Active Not RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
2Active Not RecruitingTreatmentLung Cancers1
2Active Not RecruitingTreatmentPeritoneal Mesotheliomas / Pleural Mesotheliomas1
2CompletedTreatmentAdenocarcinoma of the Prostate1
2CompletedTreatmentLeukemia, Mast-Cell1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein tyrosine kinase activity
Specific Function:
Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation,...
Gene Name:
IGF1R
Uniprot ID:
P08069
Molecular Weight:
154791.73 Da
Comments
comments powered by Disqus
Drug created on November 18, 2007 11:27 / Updated on August 17, 2016 12:24